Orteronel Does Not Improve Overall Survival in Prostate Cancer
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
There was no significant benefit with long-term ADT, but researchers said there was a “clinically relevant” benefit in patients with high-risk disease.
Between March 2020 and March 2021, the estimated number of missed prostate cancer diagnoses ranged from 97 cases to 573 cases.
Immune checkpoint inhibitors were more effective than taxanes in patients with a high tumor mutational burden.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
An analysis revealed a link between treatment with androgen deprivation therapy and new diagnoses of incident depression and anxiety in men with prostate cancer.
Patients with perineural invasion had a 4-fold higher risk of biochemical recurrence.
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
In patients with high-risk prostate cancer, negative PSMA PET/CT does not permit PLND avoidance, investigators cautioned.